WO2014002108A1 - Nanostructure noyau-coquille basée sur des protéines avec des agents thérapeutiques correspondants - Google Patents

Nanostructure noyau-coquille basée sur des protéines avec des agents thérapeutiques correspondants Download PDF

Info

Publication number
WO2014002108A1
WO2014002108A1 PCT/IN2013/000141 IN2013000141W WO2014002108A1 WO 2014002108 A1 WO2014002108 A1 WO 2014002108A1 IN 2013000141 W IN2013000141 W IN 2013000141W WO 2014002108 A1 WO2014002108 A1 WO 2014002108A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
therapeutic
core
composition
shell
Prior art date
Application number
PCT/IN2013/000141
Other languages
English (en)
Inventor
Koyakutty MANZOOR
Retnakumari ARCHANA
V. Nair SHANTIKUMAR
Original Assignee
Amrita Vishwa Vidyapeetham University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrita Vishwa Vidyapeetham University filed Critical Amrita Vishwa Vidyapeetham University
Publication of WO2014002108A1 publication Critical patent/WO2014002108A1/fr
Priority to US14/585,013 priority Critical patent/US9707186B2/en
Priority to US14/732,716 priority patent/US9545382B2/en
Priority to US15/374,176 priority patent/US10143700B2/en
Priority to US15/619,559 priority patent/US20170333365A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne la conception et la synthèse d'une nanomédecine comprenant un composite protéine-protéine ou une nanoparticule noyau-coquille, une protéine portant un type de molécule thérapeutique et une seconde protéine portant un autre type de molécule thérapeutique. La formulation de nanomédecine est destinée à traiter des maladies, notamment le cancer. Pour être spécifique, l'invention est conçue pour administrer deux types différents de molécules thérapeutiques en séquence ou en combinaison au moyen d'une seule entité de nanoparticules formées par deux protéines différentes qui portent séparément deux molécules thérapeutiques.
PCT/IN2013/000141 2012-02-21 2013-03-12 Nanostructure noyau-coquille basée sur des protéines avec des agents thérapeutiques correspondants WO2014002108A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/585,013 US9707186B2 (en) 2012-02-21 2014-12-29 Core-shell particle formulation for delivering multiple therapeutic agents
US14/732,716 US9545382B2 (en) 2012-02-21 2015-06-06 Nanoparticle formulations for delivering multiple therapeutic agents
US15/374,176 US10143700B2 (en) 2013-02-19 2016-12-09 Nanoparticle formulations for delivering multiple therapeutic agents
US15/619,559 US20170333365A1 (en) 2012-02-21 2017-06-12 Core-shell particle formulation for delivering multiple therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2550/CHE/2012 2012-06-27
IN2550CH2012 2012-06-27

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/465,521 Continuation-In-Part US9402918B2 (en) 2012-02-21 2014-08-21 Core-shell particle formulation for delivering multiple therapeutic agents

Related Child Applications (5)

Application Number Title Priority Date Filing Date
PCT/IN2013/000008 Continuation-In-Part WO2013114393A1 (fr) 2012-01-04 2013-01-04 Procédé et système pour un guide électronique de programme adaptatif, "gep dans le nuage"
PCT/IN2013/000108 Continuation-In-Part WO2013124867A1 (fr) 2012-02-21 2013-02-19 Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
US14/585,013 Continuation-In-Part US9707186B2 (en) 2012-02-21 2014-12-29 Core-shell particle formulation for delivering multiple therapeutic agents
US14/732,716 Continuation-In-Part US9545382B2 (en) 2012-02-21 2015-06-06 Nanoparticle formulations for delivering multiple therapeutic agents
US15/374,176 Continuation-In-Part US10143700B2 (en) 2013-02-19 2016-12-09 Nanoparticle formulations for delivering multiple therapeutic agents

Publications (1)

Publication Number Publication Date
WO2014002108A1 true WO2014002108A1 (fr) 2014-01-03

Family

ID=48747650

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000141 WO2014002108A1 (fr) 2012-02-21 2013-03-12 Nanostructure noyau-coquille basée sur des protéines avec des agents thérapeutiques correspondants

Country Status (1)

Country Link
WO (1) WO2014002108A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138556A1 (fr) * 2013-03-07 2014-09-12 Barmarsa Research Llc Trousses et méthodes de traitement du cancer à l'aide de peptides gliadine
WO2017011618A1 (fr) * 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Conjugué de nanoparticules ciblé et procédé d'administration conjointe d'arnic et de médicament
CN111840254A (zh) * 2020-08-28 2020-10-30 湖南省肿瘤医院 纳米雄黄复合药物及其制备方法和应用
CN113041354A (zh) * 2021-03-30 2021-06-29 广州中医药大学(广州中医药研究院) 一种特异性水解模板蛋白分子的纳米粒及其制备方法与应用
CN113521034A (zh) * 2021-08-16 2021-10-22 中新国际联合研究院 一种抗皮肤光老化的复合纳米颗粒及其制备方法
CN114015094A (zh) * 2022-01-07 2022-02-08 中国农业大学 一种高强度大麦醇溶蛋白壳聚糖复合膜及其制备方法
CN114129571A (zh) * 2021-11-30 2022-03-04 福州大学 一种基于金属-有机共组装的无载体纳米药物及其制备与应用
CN115350283A (zh) * 2022-03-22 2022-11-18 四川大学 一种碳水化合物功能化纳米颗粒及其制备方法与应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6713083B1 (en) * 1996-03-15 2004-03-30 Johnson & Johnson Medical, Ltd. Coated bioabsorbable beads for wound treatment
US20050037989A1 (en) 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US20090196933A1 (en) 2005-08-31 2009-08-06 Tapas De Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
US7838512B2 (en) 1994-02-04 2010-11-23 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US7838512B2 (en) 1994-02-04 2010-11-23 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
US6713083B1 (en) * 1996-03-15 2004-03-30 Johnson & Johnson Medical, Ltd. Coated bioabsorbable beads for wound treatment
US20050037989A1 (en) 2001-08-27 2005-02-17 Lewis David L. Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
US20090196933A1 (en) 2005-08-31 2009-08-06 Tapas De Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20100112077A1 (en) 2006-11-06 2010-05-06 Abraxis Bioscience, Llc Nanoparticles of paclitaxel and albumin in combination with bevacizumab against cancer
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138556A1 (fr) * 2013-03-07 2014-09-12 Barmarsa Research Llc Trousses et méthodes de traitement du cancer à l'aide de peptides gliadine
US9254308B2 (en) 2013-03-07 2016-02-09 Barmarsa Research Llc Kits and methods for the treatment of cancer using gliadin peptides
US9669068B2 (en) 2013-03-07 2017-06-06 Barmarsa Research Llc Methods for the treatment of cancer using gliadin peptides
WO2017011618A1 (fr) * 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Conjugué de nanoparticules ciblé et procédé d'administration conjointe d'arnic et de médicament
US10426842B2 (en) 2015-07-15 2019-10-01 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of siRNA and drug
CN111840254A (zh) * 2020-08-28 2020-10-30 湖南省肿瘤医院 纳米雄黄复合药物及其制备方法和应用
CN113041354A (zh) * 2021-03-30 2021-06-29 广州中医药大学(广州中医药研究院) 一种特异性水解模板蛋白分子的纳米粒及其制备方法与应用
CN113041354B (zh) * 2021-03-30 2022-12-23 广州中医药大学(广州中医药研究院) 一种特异性水解模板蛋白分子的纳米粒及其制备方法与应用
CN113521034A (zh) * 2021-08-16 2021-10-22 中新国际联合研究院 一种抗皮肤光老化的复合纳米颗粒及其制备方法
CN114129571A (zh) * 2021-11-30 2022-03-04 福州大学 一种基于金属-有机共组装的无载体纳米药物及其制备与应用
CN114129571B (zh) * 2021-11-30 2023-11-14 福州大学 一种基于金属-有机共组装的无载体纳米药物及其制备与应用
CN114015094A (zh) * 2022-01-07 2022-02-08 中国农业大学 一种高强度大麦醇溶蛋白壳聚糖复合膜及其制备方法
CN114015094B (zh) * 2022-01-07 2022-03-11 中国农业大学 一种高强度大麦醇溶蛋白壳聚糖复合膜及其制备方法
CN115350283A (zh) * 2022-03-22 2022-11-18 四川大学 一种碳水化合物功能化纳米颗粒及其制备方法与应用
CN115350283B (zh) * 2022-03-22 2024-01-26 四川大学 一种碳水化合物功能化纳米颗粒及其制备方法与应用

Similar Documents

Publication Publication Date Title
US9707186B2 (en) Core-shell particle formulation for delivering multiple therapeutic agents
Miao et al. Nanoformulations for combination or cascade anticancer therapy
WO2014002108A1 (fr) Nanostructure noyau-coquille basée sur des protéines avec des agents thérapeutiques correspondants
El-Readi et al. Cancer nanomedicine: a new era of successful targeted therapy
Gandhi et al. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances
Luk et al. Cell membrane-camouflaged nanoparticles for drug delivery
Orthaber et al. Skin cancer and its treatment: novel treatment approaches with emphasis on nanotechnology
Liu et al. Cancer targeted therapeutics: From molecules to drug delivery vehicles
Hashemi et al. Aptamer-conjugated PLGA nanoparticles for delivery and imaging of cancer therapeutic drugs
Zhou et al. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells
Yang et al. Nucleolin-targeting AS1411-aptamer-modified graft polymeric micelle with dual pH/redox sensitivity designed to enhance tumor therapy through the codelivery of doxorubicin/TLR4 siRNA and suppression of invasion
US10143700B2 (en) Nanoparticle formulations for delivering multiple therapeutic agents
Son et al. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors
Mohamed et al. Polymeric nano-micelles: versatile platform for targeted delivery in cancer
Kong et al. Nanoparticle drug delivery systems and their applications as targeted therapies for triple negative breast cancer
Hong et al. Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis
Jiang et al. Poly (l-glutamic acid)-cisplatin nanoformulations with detachable PEGylation for prolonged circulation half-life and enhanced cell internalization
Cao et al. Polymer nanoparticulate drug delivery and combination cancer therapy
Hu et al. Combinational chemoimmunotherapy for breast cancer by codelivery of doxorubicin and PD-L1 siRNA using a PAMAM-incorporated liposomal nanoplatform
EP3289084B1 (fr) Inhibition par arnsi de l'expression de l'antigène r humain pour le traitement du cancer
Jeswani et al. Advances in the delivery of cancer therapeutics: a comprehensive review
Liu et al. Research progress of tumor targeted drug delivery based on PD-1/PD-L1
Lin et al. Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy
Narwade et al. Advanced cancer targeting using aptamer functionalized nanocarriers for site-specific cargo delivery
Dinakar et al. Organ-restricted delivery through stimuli-responsive nanocarriers for lung cancer therapy

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13734519

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13734519

Country of ref document: EP

Kind code of ref document: A1